Bioceres price target lowered to $5 from $8 at Lake Street

Lake Street analyst Ben Klieve lowered the firm’s price target on Bioceres (BIOX) to $5 from $8 and keeps a Buy rating on the shares. Q4 results were materially below all estimates in each segment, though the firm believes FY25 will prove to be an EBITDA trough and sees value in the next-generation products throughout Bioceres’ portfolio, the analyst tells investors in a post-earnings note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, a ...